Results 21 to 30 of about 27,184 (256)

Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B

open access: yesCase Reports in Hepatology, 2023
Fanconi syndrome is a rare disease of generalized proximal tubule dysfunction which can be acquired secondary to certain medications, including tenofovir, a commonly used hepatitis B treatment.
Shirley X. Jiang   +2 more
doaj   +1 more source

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 [PDF]

open access: yes, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic ...
Ajana, F   +118 more
core   +2 more sources

A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia

open access: yesAIDS Research and Therapy, 2023
Background Bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) is approved by Federal Food and Drug Administration in 2018 for both treatment-naïve and experienced persons living with HIV (PLWH).
Kanak Parmar   +3 more
doaj   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

open access: yes, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas   +173 more
core   +2 more sources

Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV

open access: yesViruses, 2023
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens.
María F. Rombini   +13 more
doaj   +1 more source

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study [PDF]

open access: yes, 2016
BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E ...
Abram, Michael E.   +18 more
core   +1 more source

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form

open access: yesJournal of Taibah University for Science, 2019
A new simple, accurate, precise RP-HPLC [reverse phase high performance liquid chromatography] method was developed for the simultaneous estimation of the Emtricitabine, Bictegravir and Tenofovir alafenamide in pharmaceutical dosage form.
Tej Kumar Kokkirala, Duvvuri Suryakala
doaj   +1 more source

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. [PDF]

open access: yes, 2017
BackgroundThe antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease.
Chen, Ruijun   +7 more
core   +1 more source

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]

open access: yes, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...
Ajana, F   +123 more
core   +3 more sources

A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction

open access: yesBMC Infectious Diseases, 2018
Background Tenofovir alafenamide (TAF) is associated with less renal and bone toxicity compared with tenofovir disoproxil (TDF). TAF's recent FDA approval has spurred HIV providers to consider switching antiretroviral therapy (ART) regimens containing ...
Sarah S. Lee   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy